Apollo Biotech Co., Ltd.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
Assaya provides affordable and equitable human error reducing diagnostics at scale, with real-time reporting. Our mission is to provide the world with reliable, augmented, practical, and inexpensive diagnostics (RAPID) that can be deployed anywhere, anytime, to identify biomarkers and dangerous pathogens in near real-time. We help people everywhere shift from illness to wellness, and prevent the spread of disease, in a sustainable and ethically responsible manner.
Founded Year
2020
Unified Business No.
83123696
Status
Active
Number of Employees
0
Total Paid-in
Capital
500,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Assaya is a medical technology company that is revolutionizing the way rapid diagnostics are conducted and interpreted. The company's flagship products, the iaX Universal Rapid Diagnostic Reader and LEIQA RDTs, offer a number of advantages over traditional rapid diagnostic tests, including:
